These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25596202)

  • 21. Comparison of the prevalence of common bacterial pathogens in the oropharynx and nasopharynx of gambian infants.
    Odutola A; Antonio M; Owolabi O; Bojang A; Foster-Nyarko E; Donkor S; Adetifa I; Taylor S; Bottomley C; Greenwood B; Ota M
    PLoS One; 2013; 8(9):e75558. PubMed ID: 24086570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
    Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
    JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix
    Kawade A; Dayma G; Apte A; Telang N; Satpute M; Pearce E; Roalfe L; Patil R; Wang Y; Noori N; Gondhali A; Juvekar S; Oron AP; Sanghavi S; Goldblatt D; Dagan R; Bavdekar A
    Vaccine; 2023 May; 41(19):3066-3079. PubMed ID: 37045679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in Pneumococcal and
    Martinovich KM; Rahman T; de Gier C; Seppanen EJ; Orami T; Granland CM; Francis J; Yoannes M; Corscadden KJ; Ford R; Jacoby P; van den Biggelaar AHJ; Bakaletz LO; Cripps AW; Lehmann D; Richmond PC; Pomat WS; Kirkham LS; Thornton RB
    Front Immunol; 2021; 12():725244. PubMed ID: 34447389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nasopharyngeal Bacterial Carriage in the Conjugate Vaccine Era with a Focus on Pneumococci.
    Devine VT; Jefferies JM; Clarke SC; Faust SN
    J Immunol Res; 2015; 2015():394368. PubMed ID: 26351646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
    Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
    BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.
    Temple B; Tran HP; Dai VTT; Bright K; Uyen DY; Balloch A; Licciardi P; Nguyen CD; Satzke C; Smith-Vaughan H; Nguyen TV; Mulholland K
    BMJ Open; 2021 Nov; 11(11):e056505. PubMed ID: 34845082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland K; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield MD; Lehmann D; Brennan-Jones CG; Binks MJ; Licciardi PV; Andrews RM; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
    PLoS Med; 2024 Jun; 21(6):e1004375. PubMed ID: 38829821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Conjugated pneumococcal vaccines].
    Reinert P
    Arch Pediatr; 1999; 6 Suppl 3():643s-646s. PubMed ID: 10429806
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.
    van Gils EJ; Veenhoven RH; Hak E; Rodenburg GD; Bogaert D; Ijzerman EP; Bruin JP; van Alphen L; Sanders EA
    JAMA; 2009 Jul; 302(2):159-67. PubMed ID: 19584345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.
    Prymula R; Schuerman L
    Expert Rev Vaccines; 2009 Nov; 8(11):1479-500. PubMed ID: 19863240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2016 Sep; 63(5):611-8. PubMed ID: 27225239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
    Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
    Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Passive immunization for the prevention of otitis media.
    Englund JA; Glezen WP
    Vaccine; 2000 Dec; 19 Suppl 1():S116-21. PubMed ID: 11163474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.